Enter the e-mail address you used when you registered an account with IIR Energy.
A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.
Indian vaccine-maker Bharat Serums and Vaccines Limited (BSVL) said it has received approval from the Drug Controller General of India (DCGI) to conduct the Phase III clinical trial of Sepsis drug Ulinastatin on COVID-19 patients showing mild-to-moderate acute respiratory distress symptoms.
Ulinastatin is used in India, China and Japan in the treatment of severe sepsis and other critical clinical conditions such as acute pancreatitis. Clinical trials to evaluate efficacy of the drug are likely to commence soon in six hospitals across India, enrolling 120 patients. Results are expected to be available by December 2020.
|Listen to Today's News||News Audio Library||Sync News Podcasts|
This article is free for all Registered Members.
Register Now! All Fields are Required...
Upgrade your Premium News Subscription to include all archived articles for only $160. Contact Member Services: 800-762-3361
All Members Receive the Following Free Resources: